100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)
The Response of Reducing Dose of Peginterferon Alfa-2a in Koreans With Chronic Hepatitis C Genotype 1; Randomized Controlled Multicenter Study 100% Versus 80%
Sponsor: Chungnam National University
This PHASE4 trial investigates IL28B Polymorphism and Sustained Virologic Response and is currently completed. Chungnam National University leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Apr 2019 — Feb 2020 [monthly]
Completed PHASE4
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chungnam National University
- Hallym University Medical Center
- Inha University Hospital
- Inje University
- Keimyung University
- Konyang University Hospital
- Kyungpook National University Hospital
- National Health Insurance Service Ilsan Hospital
- Soonchunhyang University Hospital
- The Catholic University of Korea
- Ulsan University Hospital
- Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bucheon-si, South Korea
- • Chunchun, South Korea
- • Daegu, South Korea
- • Daejun, South Korea
- • Incheon, South Korea
- • Koyang-si, South Korea
- • Pusan, South Korea
- • Seoul, South Korea
- • Ulsan, South Korea
- • Wŏnju, South Korea